I suppose safety ultimately did VX135 in as there is dose response from 100mg to 200mg from this trial, SVR4 73 vs 83%. I don't know whether new CMO hiring implies revival of its antiviral roots, moving more aggressively with VX765 (HIV), VX787 (influenza), VX135 (HCV). I hope not. I'd rather see them moving on with CF and other orphan indications.
Re: Interim phase-2 data on VX-135 + Daclatasvir It simply looks like VX-135 doesn't have what it takes for a component in a combo to compete with what GILD and ABBV have.
Market Data 
Markets 
AI
